{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:41:38Z","timestamp":1788792098405,"version":"build-2803163510"},"reference-count":35,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Blood Res"],"DOI":"10.62347\/wdwe6603","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T02:22:33Z","timestamp":1746757353000},"page":"9-19","source":"Crossref","is-referenced-by-count":5,"title":["Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL: a systematic review and meta-analysis"],"prefix":"10.62347","volume":"15","author":[{"given":"Mohammad Amin","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Baliakas P, Espinet B, Mellink C, Jarosova M, Athanasiadou A, Ghia P, Kater AP, Oscier D, Haferlach C and Stamatopoulos K. Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations. Hemasphere 2022; 6: e707.","DOI":"10.1097\/HS9.0000000000000707"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","unstructured":"Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M and Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 2020; 135: 1859-1869.","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Brieghel C, Galle V, Agius R, da Cunha-Bang C, Andersen MA, Vlummens P, Mattsson M, Rosenquist R, Smedby KE, Herling CD, Bahlo J, Hallek M, Lundgren JD, Offner F and Niemann CU. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait? Eur J Haematol 2022; 108: 369-378.","DOI":"10.1111\/ejh.13743"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1182\/blood-2009-04-214346","article-title":"Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clínic of Barcelona experience","volume":"114","author":"Abrisqueta","year":"2009","unstructured":"Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, Muntañola A, Rozman M, Villamor N, Hodgson K, Campo E, Bosch F and Montserrat E. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clínic of Barcelona experience. Blood 2009; 114: 2044-50.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1001\/jama.2014.14553","article-title":"Chronic lymphocytic leukemia: a clinical review","volume":"312","author":"Nabhan","year":"2014","unstructured":"Nabhan C and Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA 2014; 312: 2265-76.","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN and Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-34.","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF and Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745-2760.","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic lymphocytic leukaemia","volume":"404","author":"Jain","year":"2024","unstructured":"Jain N, Wierda WG and O’Brien S. Chronic lymphocytic leukaemia. Lancet 2024; 404: 694-706.","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","unstructured":"Hallek M and Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol 2021; 96: 1679-1705.","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L and Xiao W. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36: 1720-1748.","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","article-title":"The pathogenesis of chronic lymphocytic leukemia","volume":"9","author":"Zhang","year":"2014","unstructured":"Zhang S and Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol 2014; 9: 103-18.","journal-title":"Annu Rev Pathol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","unstructured":"Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med 2020; 383: 460-473.","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00277-012-1460-z","article-title":"Immunological aspects in chronic lymphocytic leukemia (CLL) development","volume":"91","author":"Garc&#xED","year":"2012","unstructured":"García-Muñoz R, Roldan Galiacho V and Llorente L. Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol 2012; 91: 981-96.","journal-title":"Ann Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.3324\/haematol.2020.254474","article-title":"Novel use for selective inhibitors of nuclear export in β-thalassemia: block of HSP70 export from the nucleus via exportin Xpo1 improves ineffective erythropoiesis","volume":"105","author":"Modepalli","year":"2020","unstructured":"Modepalli S and Hattangadi SM. Novel use for selective inhibitors of nuclear export in β-thalassemia: block of HSP70 export from the nucleus via exportin Xpo1 improves ineffective erythropoiesis. Haematologica 2020; 105: 2188-2189.","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","unstructured":"Bosch F and Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol 2019; 16: 684-701.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/ajh.24808","article-title":"IGHV mutational status testing in chronic lymphocytic leukemia","volume":"92","author":"Crombie","year":"2017","unstructured":"Crombie J and Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol 2017; 92: 1393-1397.","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Shadman M, Liu C, Eakle K, Hiew HJ, Biondo JML, Ghia P and Mato AR. COVID-19 vaccination response and its practical application in patients with chronic lymphocytic leukemia. Hemasphere 2022; 7: e811.","DOI":"10.1097\/HS9.0000000000000811"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L and Flinn IW. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 43-56.","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"TD","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M and Tallman M. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019; 381: 432-443.","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR and Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 2021; 397: 892-901.","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J and Abdel-Wahab O. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N Engl J Med 2022; 386: 735-743.","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","unstructured":"Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J and Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL. Blood 2022; 139: 1794-1806.","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","article-title":"State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019","volume":"7","author":"Lemal","year":"2019","unstructured":"Lemal R and Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer 2019; 7: 202.","journal-title":"J Immunother Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"JA","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O’Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH and Melenhorst JJ. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018; 24: 563-571.","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1182\/blood.V122.21.873.873","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL","volume":"122","author":"Porter","year":"2013","unstructured":"Porter DL, Kalos M, Frey NV, Grupp SA, Loren AW, Jemision C, Gilmore J, McConville H, Capobianchi J, Lledo L, Chew A, Shen A, Wood PA, Litchman M, Zheng Z, Levine BL and June CH. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Blood 2013; 122: 873.","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/blood.V124.21.1982.1982","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL","volume":"124","author":"Porter","year":"2014","unstructured":"Porter DL, Frey NV, Melenhorst JJ, Hwang WT, Lacey SF, Shaw P, Chew A, Grupp SA, Capobianchi J, Gilmore J, Kalos M, Litchman M, Lledo L, Loren AW, Mahnke Y, Marcucci KT, Mcconville H, Shen A, Wood PA, Zheng Z, Levine BL and June CH. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Blood 2014; 124: 1982.","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Porter DL, Frey NV, Melenhorst JJ, Hwang WT, Lacey SF, Shaw PA, Chew A, Marcucci K, Gill S, Loren AW, Mato AR, Schuster SJ, Lledo L, McConville H, Gilmore J, Capobianchi J, Kalos MD, Grupp SA, Levine BL and June CH. Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R\/R) CLL. Journal of Clinical Oncology; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.3009"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","unstructured":"Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH and Porter DL. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J Clin Oncol 2020; 38: 2862-2871.","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4049\/jimmunol.1500751","article-title":"Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street","volume":"195","author":"DM","year":"2015","unstructured":"Barrett DM, Grupp SA and June CH. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol 2015; 195: 755-61.","journal-title":"J Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/ph7121049","article-title":"Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors","volume":"7","author":"Fujiwara","year":"2014","unstructured":"Fujiwara H. Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals (Basel) 2014; 7: 1049-68.","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","unstructured":"Chmielewski M, Hombach AA and Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 2013; 4: 371.","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","unstructured":"Srivastava S and Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol 2015; 36: 494-502.","journal-title":"Trends Immunol"},{"key":"ref32","unstructured":"American Cancer Society. CAR T-cell therapy and its side effects. Available from: https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/treatment-types\/immunotherapy\/car-t-cell1.html."},{"key":"ref33","unstructured":"National Cancer Institute. CAR T cells: engineering patients’ immune cells to treat their cancers. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/blood-2015-09-670802","article-title":"Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions","volume":"126","author":"Freeman","year":"2015","unstructured":"Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M, Salles G and Cartron G. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood 2015; 126: 2646-9.","journal-title":"Blood"}],"container-title":["American Journal of Blood Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajbr\/15\/2\/ajbr0162518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:37Z","timestamp":1766022937000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajbr\/15\/2\/ajbr0162518.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/wdwe6603","relation":{},"ISSN":["2160-1992"],"issn-type":[{"value":"2160-1992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}